HF Advocating for People with IH at Scientific Symposium

The Hypersomnia Foundation (HF) was delighted to participate in this September’s 7th International Symposium on Narcolepsy. The HF was invited, along with three other patient advocacy groups “to bring important and diverse perspectives on how best to advocate for and support patients with narcolepsy and related disorders such as idiopathic hypersomnia.” The event was co-directed by Kiran Maski, MD, HF Medical Advisory Board (MAB) member.

The previous meeting of this group was held in 2009 in Switzerland, and a book was published in 2011 as a summary of that meeting. Papers will be forthcoming from this Symposium, and HF MAB members Lynn Marie Trotti, MD, MSc, and Isabelle Arnulf, MD, PhD, will be collaborating with other colleagues on a paper differentiating narcolepsy type 1 from idiopathic hypersomnia.

Mary King, EdD, and Cat Rye, members of the HF Board of Directors, attended the Symposium and gave a brief presentation to the attendees following an evening dinner. They described the mission of the HF, the current works-in-progress, and the results of a patient focus-group discussion about those HF initiatives of significance to their quality of life. In addition, the board members chaired an exhibit booth and provided information about the HF, the CoRDS Registry, the HF Research Award Program, and the HF Anesthesia Guide and Patient Care Plan. Discussing the Foundation with attendees in this way provided great networking opportunities for the HF Board and the HF’s Scientific and Medical Advisory Board (SAB and MAB, respectively) members.

Prof. King and Ms. Rye attended several of the scientific talks that addressed multidisciplinary updates and diagnostic criteria on the basic and clinical aspects of narcolepsy. This year, for the first time, idiopathic hypersomnia was included in the conversation. Along with clinical and scientific sessions, the Symposium also had poster presentations and debates that included about “100 highly respected researchers, clinicians, and patient advocates from around the world…” Chad Ruoff, MD, (HF MAB) was lead author of a poster session titled, “The MSLT is Repeatable in Narcolepsy Type 1 but Not Narcolepsy Type 2: A Retrospective Study.”

During the plenary session Emerging Treatments 1, David Rye, MD, PhD, (HF SAB) discussed the larger role of newer treatments, GABA modulators. In addition, Dr. Lynn Marie Trotti presented data from the HF Hypersomnia Registry at CoRDS in a session of the segment Novel Diagnostics and NT2 vs. IH, titled “Sleep inertia characteristics in idiopathic hypersomnia and the narcolepsies within the Hypersomnia Foundation Registry.” Dr. Isabelle Arnulf (HF MAB) gave an interesting talk titled “Creative Thinking in Narcolepsy.” The HF board members attended the session titled “Ideas for ICSD-4” where they shared information, made observations, and raised questions on behalf of the IH community. Dr. Trotti and Dr. Maski, along with two other colleagues, co-led that session.

This update is also featured on our Global Giving page, along with a link to the HF’s brief Symposium PowerPoint Presentation. Visit Global Giving or our Donation page to help support the mission of the Hypersomnia Foundation.

Share Post
FacebookTwitterLinkedInEmailShare

SomnusNooze Home Page

SomnusNooze Editions/Archives
Disclaimer

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.